10:44:15 EDT Wed 16 Oct 2019
Enter Symbol
or Name
USA
CA



Imagin Medical Inc
Symbol C : IME
Shares Issued 139,060,278
Close 2019-08-27 C$ 0.06
Recent Sedar Documents

Imagin Medical spends $659,836 on R&D in Q3 FY 2019

2019-08-27 16:12 ET - News Release

Mr. Jim Hutchens reports

IMAGIN MEDICAL REPORTS FISCAL 2019 THIRD QUARTER RESULTS

Imagin Medical Inc. has released financial results for the three months ended June 30, 2019. All amounts, unless otherwise specified, are presented in accordance with international financial reporting standards (IFRS).

Recent corporate developments:

  • In April, 2019, Imagin reached a major product development milestone with completion of the i/Blue imaging system's initial functional unit, which met the company's pre-established performance expectations.
  • At the American Urology Association's annual meeting, held May 3 to May 6 in Chicago, Ill., Imagin held private focus groups, where leading urologists assessed the first initial functional product and provided feedback that was used to finalize the i/Blue product's user needs.
  • In July, 2019, Imagin reported that it had moved to step five of the seven-step development process that the U.S. Food and Drug Administration (FDA) defines in its design control guidance for medical device manufacturers: (1) user needs; (2) design input; (3) design process; (4) design output; (5) design verification; (6) device realization; and finally, (7) device validation.
  • Imagin has continued to refine the i/Blue imaging system's regulatory strategy and is planning for a second meeting to be held with the FDA in the near future to further discuss the technology's regulatory pathway.

"Using the overwhelmingly positive feedback gathered from focus groups of leading urologists, we are excited about the strides that the company has made in moving the functional phase of i/Blue system's development forward this quarter," said Jim Hutchens, Imagin's president and chief executive officer. "We are currently in the process of finalizing additional functional units that will undergo the requisite testing for electrical, safety, software and other standards. Once this verification testing has been completed, we will initiate step six: device realization.

"In parallel with continuing i/Blue's technical progress, we are looking forward to introducing a number of initiatives over the next few months designed to increase investor awareness about Imagin and the significant commercial opportunity that we see ahead," commented Mr. Hutchens. "These will include outreach via non-deal road shows and various social media channels."

Summary third quarter fiscal 2019 financial results

Total operating expenses for the third quarter of fiscal 2019 were $1,201,379, compared with $1,751,665 for the same quarter in 2018, and consisted primarily of research and development (R&D) and general and administrative (G&A) expenses. R&D expenses for the third quarter of fiscal 2019 were $659,836 compared with $294,942 in the same quarter in 2018. The increase in R&D was primarily attributable to development, design, engineering and regulatory expenses. G&A expenses for the third quarter of fiscal 2019 were $348,092 compared with $667,560 for the same quarter in 2018. The change in G&A expenses was primarily attributable to the decrease in consulting fees as there were no expenses related to raising capital during the third quarter of fiscal 2019.

Net loss for the three months ended June 30, 2019, was $1,201,379, or a one-cent loss per common share, compared with a net loss of $1,751,665, or a two-cent loss per common share, for the three months ended June 30, 2018.

Liquidity and outstanding share capital

As at June 30, 2019, the company had cash of $3,407,833.

As at Aug. 28, 2019, Imagin had an unlimited number of authorized common shares with 139,060,278 common shares issued and outstanding.

The company's financial statements and management's discussion and analysis are available on SEDAR.

Conference call details

Imagin is pleased to invite all interested parties to participate in a conference call scheduled for Sept. 5, 2019, at 5 p.m. ET, during which the results will be discussed.

Live call:  844-407-9500 (Canada and the United States) or 862-298-0850 (international)

Replay:  877-481-4010 (Canada and the United States)

Replay ID:  53532

The call will also be broadcast live and archived on the company's website under events and presentations.

About Imagin Medical Inc.

Imagin Medical is a surgical imaging company focused on establishing a new standard of care in visualizing cancer during minimally invasive surgeries (MIS). The company's first product, the i/Blue imaging system, is based on advanced optics and light sensors and employs patented ultrasensitive imaging technology. The company believes the i/Blue system, with easy-to-use imaging options, will significantly improve surgeons' ability to visualize cancerous cells for more accurate resection. The company's initial focus is bladder cancer.

We seek Safe Harbor.

© 2019 Canjex Publishing Ltd. All rights reserved.